Back to top

Image: Bigstock

Oscar Health (OSCR) Reports Q3 Earnings: What Key Metrics Have to Say

Read MoreHide Full Article

For the quarter ended September 2026, Oscar Health, Inc. (OSCR - Free Report) reported revenue of $5.14 billion, up 72.1% over the same period last year. EPS came in at $0.49, compared to -$0.53 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $4.72 billion, representing a surprise of +8.84%. The company delivered an EPS surprise of +545.46%, with the consensus EPS estimate being -$0.11.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Oscar Health performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
  • Membership by Offering- Individual and Small Group: 2.69 million compared to the 2.7 million average estimate based on two analysts.
  • Medical loss ratio: 84% compared to the 85.1% average estimate based on two analysts.
  • Revenue- Premium: $5.04 billion compared to the $4.66 billion average estimate based on two analysts. The reported number represents a change of +72.4% year over year.
  • Revenue- Administrative services revenue (Other revenues): $6.3 million versus the two-analyst average estimate of $6.9 million.
  • Revenue- Investment income: $91.02 million compared to the $58.14 million average estimate based on two analysts. The reported number represents a change of +71% year over year.

View all Key Company Metrics for Oscar Health here>>>

Shares of Oscar Health have returned +6.9% over the past month versus the Zacks S&P 500 composite's -0.4% change. The stock currently has a Zacks Rank #1 (Strong Buy), indicating that it could outperform the broader market in the near term.

Published in